Citadel Advisors’s Surgalign Holdings, Inc. Common Stock SRGA Stock Holding History

Citadel Advisors’s Portfolio SRGA Stock Details SRGA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-840	Closed	-$27K	–	15350
2021 Q3	$27K	Sell	840 -2,143	-72%	-$78.5K	﹤0.01%	13598
2021 Q2	$124K	Sell	2,983 -194	-6%	-$9.94K	﹤0.01%	12719
2021 Q1	$208K	Buy	+3,177	New	+$222K	﹤0.01%	11624

Other funds holding SRGA

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

WWP

WR Wealth Planners Columbia, Missouri $311M AUM 18.22% 1-Year Est. Return

Citadel Advisors's SRGA Position: Q3 2023 in Review

Citadel Advisors sold out of Surgalign Holdings, Inc. Common Stock (SRGA) in Q3 2023, closing a stake of 25,840 shares — an estimated $4.73K sold.

Citadel Advisors first reported a position in SRGA in Q2 2013 and held it in 28 quarters. The position peaked at $1.66M in Q2 2015. 4 funds tracked by Wall St. Rank hold SRGA as of Q3 2023.

Citadel Advisors reported no remaining Surgalign Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 25,840 Surgalign Holdings, Inc. Common Stock shares in Q3 2023, an estimated $4.73K.
Citadel Advisors first reported a position in Surgalign Holdings, Inc. Common Stock in Q2 2013 and held it in 28 quarters.
Citadel Advisors's Surgalign Holdings, Inc. Common Stock position peaked at $1.66M in Q2 2015.
4 funds tracked by Wall St. Rank held Surgalign Holdings, Inc. Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.